Optimization of Human Mesenchymal Stem Cells for Rheumatoid Arthritis: Implications for Improved Therapeutic Outcomes

por Breitman, Maya, Bonfield, Tracey L., Caplan, Arnold I., Lazarus, Hillard M., Haghiac, Maricela, LaSalvia, Susan, Reese‐Koc, Jane, Singer, Nora G.
Publicado 2021

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

por Bonfield, Tracey L., Sutton, Morgan T., Fletcher, David R., Reese-Koc, Jane, Roesch, Erica A., Lazarus, Hillard M., Chmiel, James F., Caplan, Arnold I.
Publicado 2023

Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria

por Ahmed, Nausheen, Li, Lucy, Rojas, Patricio, Covut, Fahrettin, Reese-Koc, Jane, Kolk, Merle, Malek, Ehsan, Metheny, Leland, O’Brien, Timothy, Caimi, Paolo, de Lima, Marcos, Cooper, Brenda W.
Publicado 2021

Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens

por Wang, Jiasheng, Sanati, Farhad, Firoozmand, Amin, Fu, Pingfu, Kolk, Merle, Reese-Koc, Jane, de Lima, Marcos, Boughan, Kirsten, Cooper, Brenda, Caimi, Paolo, Gallogly, Molly, Otegbeye, Folashade, Tomlinson, Benjamin, Metheny, Leland
Publicado 2023

Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis

por Planchon, Sarah M, Lingas, Karen T, Reese Koç, Jane, Hooper, Brittney M, Maitra, Basabi, Fox, Robert M, Imrey, Peter B, Drake, Kylie M, Aldred, Micheala A, Lazarus, Hillard M, Cohen, Jeffrey A
Publicado 2018

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells

por Zeng, Ke, Huang, Meixian, Lyu, Mi-Ae, Khoury, Joseph D., Ahmed, Sairah, Patel, Krina K., Dropulić, Boro, Reese-Koc, Jane, Caimi, Paolo F., Sadeghi, Tara, de Lima, Marcos, Flowers, Christopher R., Parmar, Simrit
Publicado 2023

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

por Caimi, Paolo F., Pacheco Sanchez, Gabriela, Sharma, Ashish, Otegbeye, Folashade, Ahmed, Nausheen, Rojas, Patricio, Patel, Seema, Kleinsorge Block, Sarah, Schiavone, Jennifer, Zamborsky, Kayla, Boughan, Kirsten, Hillian, Antoinette, Reese-Koc, Jane, Maschan, Mikhail, Dropulic, Boro, Sekaly, Rafick-Pierre, de Lima, Marcos
Publicado 2021

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

por Maschan, Michael, Caimi, Paolo F., Reese-Koc, Jane, Sanchez, Gabriela Pacheco, Sharma, Ashish A., Molostova, Olga, Shelikhova, Larisa, Pershin, Dmitriy, Stepanov, Alexey, Muzalevskii, Yakov, Suzart, Vinicius G., Otegbeye, Folashade, Wald, David, Xiong, Ying, Wu, Darong, Knight, Adam, Oparaocha, Ibe, Ferencz, Beatrix, Roy, Andre, Worden, Andrew, Kruger, Winfried, Kadan, Michael, Schneider, Dina, Orentas, Rimas, Sekaly, Rafick-Pierre, de Lima, Marcos, Dropulić, Boro
Publicado 2021